Lv11
48 积分 2024-05-25 加入
89P Hepatic arterial infusion chemotherapy sequential transarterial embolization combined with lenvatinib and tislelizumab in patients with high-risk unresectable hepatocellular carcinoma: A single arm phase II trial
3小时前
已关闭
209P Hepatic arterial infusion chemotherapy sequential transarterial embolization combined with lenvatinib and tislelizumab in patients with high-risk unresectable hepatocellular carcinoma: A phase II trial
3小时前
已关闭
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
5天前
已完结
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium
5天前
已完结
Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline
5天前
已完结
Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients
6天前
已完结
Molecularly targeted therapy in hepatocellular carcinoma
6天前
已完结
Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro
6天前
已关闭
Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma
6天前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
12天前
已完结
皖公网安备34019202002308
